Investors

Technology, Market, and Team.

Technology: We are an award-winning clinical stage biotechnology company. We have identified a novel molecular target for Triple Negative Breast Cancer and are developing innovative therapies for its treatment. We believe that our unique therapy will be effective for the treatment of the different heterogenic subtypes and ethnic groups of Triple Negative Breast Cancer. We are currently focused on the R & D of our novel first-in-class drug candidate and have recently completed animal studies to evaluate its efficacy in female mice implanted with Triple Negative Breast Cancer cell xenograft. We hold 4 US patents and have submitted PCT-National Stage filing for US and Europe PCT, for our technology. We are also developing Companion Diagnostics for the detection of Triple Negative Breast Cancer.  

 Market: According to WHO, there were 2.8 million new cases of breast cancer, diagnosed worldwide, in 2020. The global cancer therapy market is estimated to be valued at $220 billion in 2024, witnessing a CAGR of 8.37%, according to Mordor Intelligence. According to Global Market Insights, the breast cancer therapy market is projected to hit $48 billion by 2029.

Team: Exceptionally qualified team of Scientists, Clinicians, Management team and Advisors with collective experience of over 125 years